NEU neuren pharmaceuticals limited

Ann: NEU confirms primary endpoints for Phase 3 trial in PMS, page-38

  1. 2,759 Posts.
    lightbulb Created with Sketch. 1062
    Your general sentiment may be accurate but it's not in NEU case. Our CEO has said we are not setup for distribution. This means we either merge, acquire, get taken over or licence to manage our inability to distribute. Our CEO stated that licencing seems boring. He has also said that they would not entertain offers until endpoints agreed and new indications named. We named a new indication in recent weeks and we now have endpoints agreed. Whilst I expect more indications to be named, I do think we are at the pointy end of having a 'for sale' sign up, and that this is far from hyperbole.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$16.48
Change
-0.290(1.73%)
Mkt cap ! $2.076B
Open High Low Value Volume
$16.58 $16.74 $16.40 $9.107M 549.9K

Buyers (Bids)

No. Vol. Price($)
1 864 $16.43
 

Sellers (Offers)

Price($) Vol. No.
$16.50 1668 1
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.